Q-omics provides the consensus-scored TLCD5 profile across patient tissues and cancer cell-line models. TLCD5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TLCD5 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TLCD5 RNA expression shows 20,301 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where TLCD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLCD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLCD5 survival associations across molecular data types. TLCD5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLCD5 RNA expression–survival associations across cancer types. High TLCD5 expression shows unfavorable associations in ACC, UVM, SCLC, LIHC and UCEC, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TLCD5 RNA expression.
This table summarizes TLCD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TLCD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLCD5 shows lower tumor expression in BLCA, LUSC and LUAD and higher tumor expression in HNSC, LIHC and KIRP. The HNSC box plot shows higher TLCD5 RNA expression in tumor versus normal tissue (log2 FC = +0.649, t-test p < 0.001).
This table shows molecular features associated with TLCD5 in patient tissues and cancer cell lines. In patient samples, TLCD5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TLCD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
